For the Inventor, By the Inventor

Enter assignee name

Copenhagen, Denmark

Genmab A+s

USPTO Granted Patents = 107

% Expired Patents = 10.3

CIPO Patents = 5

EPO Patents = 62

Trademarks = 23

Forward Citations = 1,030

Loading Chart...

Loading Chart...

154 inventors (with patents filed for the assignee):

Paul Parren (83 out of 136 patents)

Janine Schuurman (45 out of 58 patents)

Jan Van De Winkel (32 out of 45 patents)

4. David Satijn (31 out of 44 patents)

5. Aran Frank Labrijn (30 out of 37 patents)

6. Ole Baadsgaard (28 out of 31 patents)

7. Edward Norbert Van Den Brink (27 out of 57 patents)

8. Rik Rademaker (18 out of 32 patents)

9. Isil Altintas (18 out of 20 patents)

10. Joyce Meesters (15 out of 15 patents)

11. Tom Vink (15 out of 26 patents)

12. Jan G J Van De Winkel (15 out of 15 patents)

13. Joost J Neijssen (15 out of 15 patents)

14. Ugur Sahin (14 out of 195 patents)

15. Arnout F Gerritsen (14 out of 21 patents)

Core Competencies:

Monoclonal Antibodies

Bispecific Antibodies

Anti-PD-1

Anti-VEGF

CD3

CD20

CD40

CD137

Antibody-Drug Conjugates

Cancer Treatment

Heterodimeric Antibodies

Therapeutics

107 patents: Sort by Forward Citations

1. 12692320 - BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 (2026-07-28),

2. 12673994 - HUMANIZED OR CHIMERIC CD3 ANTIBODIES (2026-07-07),

3. 12617854 - HUMANIZED OR CHIMERIC CD3 ANTIBODIES (2026-05-05),

4. 12595316 - BISPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD FOR ISOLATION OF SUCH (2026-04-07),

5. 12589150 - ANTIBODIES BINDING AXL (2026-03-31),

6. 12570751 - BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF (2026-03-10),

7. 12453781 - Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate (2025-10-28),

8. 12435154 - Bispecific antibodies against CD3 and CD20 (2025-10-07),

9. 12421319 - Binding agents that bind OX40 (CD134) and method of use thereof to treat disease (2025-09-23),

10. 12415859 - Methods of producing heterodimeric antibodies (2025-09-16),

11. 12398214 - Binding agents binding to EpCAM and CD137 (2025-08-26),

12. 12351650 - Antibodies binding to fibroblast activation protein alpha and death receptor 4 (2025-07-08),

13. 12324841 - Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate (2025-06-10),

14. 12247065 - Method for producing a controlled mixture of two or more different antibodies (2025-03-11),

15. 12246025 - Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate (2025-03-11),

Genmab is an international biotechnology company that specializes in the research, development, and commercialization of antibody-based therapies to treat cancer. The company focuses on creating innovative and differentiated antibody products to address unmet medical needs. With a diverse pipeline and a track record of successful collaborations, Genmab is committed to improving the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

107 Patents

#6 in Copenhagen

#37 in Denmark

#7,326 in the World

Copenhagen, Denmark

Genmab A+s

Forward Citations = 1,030

154 inventors:

Paul Parren (83 out of 136 patents)

Janine Schuurman (45 out of 58 patents)

Jan Van De Winkel (32 out of 45 patents)

4. David Satijn (31 out of 44 patents)

5. Aran Frank Labrijn (30 out of 37 patents)

Please report any incorrect information to [email protected]

Loading…